NANO — Nanobiotix SA Share News
0.000.00%
Last trade - 00:00- €971.36m
- €967.08m
- €7.84m
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering
Europe Research Roundup: Aj Bell, Greencore, S&U
Brief: Nanobiotix Announces Pricing Of Oversubscribed €85M Global Offering
Brief: Nanobiotix Announces Trading Resumption Of Ordinary Shares On Euronext Paris
Brief: Nanobiotix Announces Launch Of Global Follow-On Offering
Brief: Nanobiotix Announces Preclinical Data On Improved Delivery, Safety Of LNP-DNA Immunotherapy
France's Nanobiotix 2025 net loss narrows as revenue rebounds
Brief: Nanobiotix S.A. FY Revenue EUR 32.6 Million
Nanobiotix jumps after media report says J&J mulls potential takeover
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Nanobiotix Sings Strategic Royalty Monetization Agreement With Healthcare Royalty
Brief: Nanobiotix Transfers Sponsorship Of Nanoray-312 To J&J
Europe Research Roundup: Banco BPM, DWS Group, UCB
Nanobiotix jumps on promising cancer therapy data
Brief: Nanobiotix S.A. H1 Revenue EUR 26.6 Million
Brief: Nanobiotix Announces Updated Phase 1 Results Continuing To Support JNJ-1900 (Nbtxr3) Plus Anti-Pd-1 As A Potential New 1L Or 2L+ Option In Anti-Pd-1 Naïve Or Resistant R/M-Hnscc